Printer Friendly

CAMBRIDGE BIOTECH CORPORATION AWARDED PATENT FOR NOVEL DRUG DELIVERY SYSTEM

 WORCESTER, Mass., Jan. 10 /PRNewswire/ -- Cambridge Biotech Corporation (NASDAQ; CBCX) today announced that it has been awarded Patent No. 5273965 from the U.S. Patent Office for a drug delivery system utilizing the saponin family of compounds, the same family from which the company's Stimulon QS-21 adjuvant is derived. The new system would permit absorption of medications by means of nasal spray or eye drops. Preliminary data have demonstrated the ability of the patented compounds to facilitate insulin transport through membranes of the eye and nose.
 "We are excited by the potential for this important new system," said Dr. Robert B. Kammer, vice president of Medical Affairs at Cambridge Biotech. "A drug delivery system that eliminates the need for expensive and painful injections would be a major benefit to patients. Additional animal studies are in progress to further define the scope of this novel delivery system. Potential applications include delivery of vaccines, existing injectable therapeutic compounds such as certain antibiotics, and biologics such as insulin, interferon, and growth hormone releasing factor (GRF)."
 Dr. Gerald Beltz, vice president of Research and Development, added, "This non-invasive system has particular promise for administration of GRF therapy, which may be effective in the treatment of osteoporosis. Cambridge Biotech is a partner in a joint venture which controls patents on manufacture and use of this promising substance. Because osteoporosis affects primarily an aging population and would include frequent treatments over an extended period, a transmucosal drug delivery system would be highly preferable to injection."
 Cambridge Biotech Corporation is a therapeutics and diagnostics company involved in infectious diseases. The company is developing vaccines, adjuvants and diagnostics for humans and animals.
 -0- 1/10/94
 /CONTACT: Frederick V. Casselman, vice president Legal Affairs & Technology Licensing, 508-797-5777; or Alyson Button Stone, coordinator of Investor Relations, 508-797-5777, ext. 541, both of Cambridge Biotech/
 (CBCX)


CO: Cambridge Biotech Corporation ST: Massachusetts IN: MTC SU:

CM-JL -- NE005 -- 0516 01/10/94 10:59 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 10, 1994
Words:323
Previous Article:AMERICAN DIGITAL COMMUNICATIONS SIGNS AGREEMENT WITH TRINITY TRADING & RESEARCH
Next Article:BURDINES DONATES DECORATED CHRISTMAS TREES TO CHARITIES THROUGHOUT FLORIDA
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters